Abstract:
N-Benzoyl arylsulfonamides having the formula (I) are BCL-Xl inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-Xl inhibiting compositions and methods of promoting apoptosis in a mammal.
Abstract:
The present invention provides a process of designing compounds which bind to a specific target molecule. The process includes the steps of a) identifying a first ligand to the target molecule using two-dimensional 15N/1H NMR correlation spectroscopy; b) identifying a second ligand to the target molecule using two-dimensional 15N/1H NMR correlation spectroscopy; c) forming a ternary complex by binding the first and second ligands to the target molecule; d) determining the three-dimensional structure of the ternary complex and thus the spatial orientation of the first and second ligands on the target molecule; and e) linking the first and second ligands to form the drug, wherein the spatial orientation of step (d) is maintained.
Abstract:
The present invention relates to 1H-benzimidazole-4-carboxamides of formula (I), their preparation, and their use as inhibitors of the enzyme poly(ADP-ribose)polymerase for the preparation of drugs.
Abstract:
Methods of detecting binding of a putative ligand to a C-enriched target molecule, methods of screening for compounds which bind to a C-enriched target molecule, methods for calculating the dissociation constant of a ligand compound which binds to a C-enriched target molecule, and methods employed in the determination of the specific amino acids in a C-enriched target molecule affected by the binding of a ligand, as well as compounds identified by these screening methods, are provided herewith.
Abstract:
The present invention provides a process of designing compounds which bind to a specific target molecule. The process includes the steps of a) identifying a first ligand to the target molecule using two-dimensional 15N/1H NMR correlation spectroscopy; b) identifying a second ligand to the target molecule using two-dimensional 15N/1H NMR correlation spectroscopy; c) forming a ternary complex by binding the first and second ligands to the target molecule; d) determining the three-dimensional structure of the ternary complex and thus the spatial orientation of the first and second ligands on the target molecule; and e) linking the first and second ligands to form the drug, wherein the spatial orientation of step (d) is maintained.
Abstract:
The present invention provides a process for identifying compounds which bin d to a specific target molecule. The process includes the steps of: a) generating a first two-dimensional 15N/1H NMR correlation spectrum of a 15N-labeled target molecule; b) exposing the labeled target molecule to one or a mixture of chemical compounds; c) generating a second two-dimensional 15N/1H NMR correlation spectrum of the labeled target molecule that has been exposed to one or a mixture of compounds in step (b); and d) comparing said first and second two-dimensional 15N/1H NMR correlation spectra to determine differenc es between said first and said second spectra, the differences indentifying the presence of one or more compounds that are ligands which ha ve bound to the target molecule.
Abstract:
Zpusob zahrnuje identifikaci sloucenin, které se vázou na specifickou cílovou molekulu. Zpusob zahrnuje tyto kroky: a) vytvorení prvního jednodimensionálního T.sub.2-.n. nebo difusne filtrovaného spektra jedné slouceniny nebo smesi chemických sloucenin; b) vystavení jedné slouceniny nebo smesi chemických sloucenin vuci cílové molekule; c) vytvorení druhého jednodimensionálního T.sub.2-.n. nebo difusne filtrovaného spektra jedné slouceniny nebo smesi chemických sloucenin, které byly vystaveny vuci cílové molekule v kroku (b); a d) porovnání uvedeného prvního a druhého jednodimensionálního T.sub.2- .n.nebo difusne filtrovaného spektra pro urcení rozdílu mezi uvedeným prvním a uvedeným druhým spektrem, pricemz tyto rozdíly identifikují prítomnost jedné nebo více sloucenin, které jsou ligandy, jez se navázaly na cílovou molekulu.